A Breakthrough in Dementia Treatment on the Horizon
Arctic Therapeutics (ATx), a pioneering Icelandic scaleup, is making waves in the fight against dementia with its innovative approach to drug development. Recently, the company secured €26.5 million in funding, a testament to growing investor confidence in its research capabilities.
How Genomics is Changing Drug Development
Founded in 2015, ATx utilizes cutting-edge genomics and bioinformatics to identify disease-associated genes. This process allows the company to create targeted treatments aimed at the root causes of conditions like dementia. According to ATx, this method significantly reduces the timelines, risks, and costs typically associated with developing new medications.
Meet the Promising Treatments: AT-001 and AT-004
With its recent funding, ATx aims to advance two primary drug candidates: AT-001 and AT-004. AT-001 is particularly exciting as it targets dementia caused by the dangerous accumulation of proteins in the brain. By disrupting these harmful clusters, AT-001 has the potential to not only halt the progression of dementia but may also delay its onset and even reverse its course.
The Future of Dementia Treatments
ATx's confidence in AT-001 stems from promising early results and the endorsement of regulators. The European Medicines Agency has approved clinical trials for the drug, which will investigate its effects on familial dementia, a rare type of the condition. Meanwhile, AT-004 aims to treat acne and other inflammatory skin issues, showcasing ATx's broad research ambitions.
A Collective Responsibility to Fight Dementia
As Svetoslava Georgieva, chair of the EIC Fund Board, highlights, dementia is a growing crisis impacting over 10 million individuals across Europe. The ongoing research by ATx not only aims to alleviate the burden on families and healthcare systems but also offers hope for transformative treatments that can redefine the future of dementia care.
Write A Comment